.png)
Reunion is a venture backed clinical-stage biopharma company committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions that serve as safe, fast-acting, short duration therapies for underserved mental health disorders, beginning with postpartum depression (PPD). We relentlessly pursue the development of safer therapeutics that provide durable antidepressive effects for the millions of people whose needs are not met by the current standard of care.
